Related Experiment Video
Updated: Jun 2, 2026
Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
Review of ceftaroline fosamil microbiology: integrated FOCUS studies
Ian A Critchley1, Paul B Eckburg, Alena Jandourek
1Cerexa, Inc., Oakland, CA 94612, USA. icritchley@cerexa.com
Abstract:
Ceftaroline fosamil, the prodrug form of ceftaroline, is a novel broad-spectrum parenteral cephalosporin that exhibits antibacterial activity against typical respiratory pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus and common Gram-negative pathogens. In particular, ceftaroline has activity against resistant Gram-positive cocci, including penicillin- and multidrug-resistant S. pneumoniae, as well as methicillin-resistant S. aureus. The activity of ceftaroline against these phenotypes is attributed to its ability to bind to modified penicillin-binding proteins with high affinity when compared with other β-lactams. The activity of ceftaroline is not compromised by the ability of H. influenzae to produce β-lactamase. Ceftaroline fosamil was compared with ceftriaxone for safety and efficacy in two randomized, double-blinded, controlled Phase III clinical trials for the treatment of community-acquired pneumonia (CAP). Microbiological assessments at baseline included respiratory specimen cultures, blood cultures, urinary antigen testing and atypical pathogen serology testing. By-subject and by-pathogen microbiological outcomes were assessed in the microbiologically evaluable population at the test-of-cure visit. The favourable microbiological response rates by subject for ceftaroline were 87.0% compared with 81.0% for ceftriaxone. The by-pathogen microbiological response rates of ceftaroline and ceftriaxone were 87.3% and 72.9% for S. pneumoniae, 83.3% and 85.0% for H. influenzae and 76.0% and 70.4% for S. aureus, respectively. Key baseline pathogens such as S. pneumoniae, H. influenzae and methicillin-susceptible S. aureus were susceptible to ceftaroline, with MIC(90)s of 0.03, 0.03 and 0.25 mg/L, respectively, supporting its utility as a promising new agent for treatment of CAP.
Insights
Ceftaroline fosamil demonstrates strong efficacy against common respiratory pathogens, including resistant strains like methicillin-resistant Staphylococcus aureus. This novel cephalosporin shows promising results for treating community-acquired pneumonia (CAP).
Area of Science:
- Pharmacology and Infectious Diseases
- Clinical Microbiology and Antibiotic Resistance
Background:
- Ceftaroline fosamil is a novel, broad-spectrum parenteral cephalosporin with activity against key respiratory pathogens.
- It exhibits potent activity against resistant Gram-positive organisms, including penicillin-resistant Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus (MRSA).
- Its mechanism involves high-affinity binding to modified penicillin-binding proteins, overcoming common resistance mechanisms like beta-lactamase production in Haemophilus influenzae.
Purpose of the Study:
- To evaluate the safety and efficacy of ceftaroline fosamil compared to ceftriaxone in treating community-acquired pneumonia (CAP).
- To assess the microbiological response rates for ceftaroline fosamil against key bacterial pathogens in CAP patients.
Main Methods:
- Two randomized, double-blinded, controlled Phase III clinical trials were conducted.
- Microbiological assessments included respiratory and blood cultures, urinary antigen testing, and atypical pathogen serology.
- Outcomes were evaluated in the microbiologically evaluable population at the test-of-cure visit, assessing both by-subject and by-pathogen response rates.
Main Results:
- Ceftaroline fosamil achieved favorable by-subject microbiological response rates of 87.0%, compared to 81.0% for ceftriaxone.
- By-pathogen response rates showed ceftaroline fosamil superiority or non-inferiority against Streptococcus pneumoniae (87.3%), Haemophilus influenzae (83.3%), and Staphylococcus aureus (76.0%).
- Low MIC(90) values (≤0.25 mg/L) were observed for key pathogens, including Streptococcus pneumoniae, Haemophilus influenzae, and methicillin-susceptible Staphylococcus aureus.
Conclusions:
- Ceftaroline fosamil demonstrated favorable safety and efficacy in treating community-acquired pneumonia (CAP).
- Its robust activity against common and resistant respiratory pathogens supports its role as a promising therapeutic agent for CAP.
- The microbiological data support the clinical utility of ceftaroline fosamil for CAP treatment.
Related Concept Videos
01:25Clinical Significance of Antibiotic Resistance
01:28Antimicrobial Effectiveness